Raymond Signore - Health Sciences Director Marketing
Insider
Raymond Signore is Director Marketing of Health Sciences Gr
Health Sciences Management Efficiency
The company has return on total asset (ROA) of (0.7297) % which means that it has lost $0.7297 on every $100 spent on assets. This is way below average. Health Sciences' management efficiency ratios could be used to measure how well Health Sciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Timothy Pigot | Aerovate Therapeutics | 53 | |
| Matthew Koder | Bank of America | 52 | |
| Gabrielle JD | PayPal Holdings | 45 | |
| MBA JD | Recursion Pharmaceuticals | 66 | |
| Aditya Bhasin | Bank of America | 50 | |
| Christopher Gibson | Recursion Pharmaceuticals | 41 | |
| Benjamin Dake | Aerovate Therapeutics | 48 | |
| Rita Cook | Bank of America | N/A | |
| Blake Borgeson | Recursion Pharmaceuticals | 42 | |
| Alfonso Villanueva | PayPal Holdings | N/A | |
| Shafique MD | Recursion Pharmaceuticals | 53 | |
| MBA MR | Aerovate Therapeutics | 62 | |
| Jeffrey Karbowski | PayPal Holdings | 46 | |
| Thomas Scrivener | Bank of America | 52 | |
| Anne Finucane | Bank of America | N/A | |
| Michael Secora | Recursion Pharmaceuticals | 41 | |
| Bernard Mensah | Bank of America | 53 | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| Amie OToole | Alphabet Inc Class C | 49 | |
| Jared Allenbach | Recursion Pharmaceuticals | N/A | |
| Bruce Thompson | Bank of America | 56 | |
Management Performance
| Return On Asset | -0.73 |
Health Sciences Gr Leadership Team
Elected by the shareholders, the Health Sciences' board of directors comprises two types of representatives: Health Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Health. The board's role is to monitor Health Sciences' management team and ensure that shareholders' interests are well served. Health Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Health Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Gaffney, Chief Pres | ||
| Allan Himmelstein, Pres Ingredients | ||
| Raymond Signore, Director Marketing | ||
| Fred Aserati, VP Devel | ||
| Jeffrey Klar, Chief Division |
Health Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Health Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.73 | |||
| Operating Margin | (73.91) % | |||
| Current Valuation | 39.41 K | |||
| Price To Sales | 0 X | |||
| Revenue | 358.43 K | |||
| Gross Profit | 22.91 K | |||
| EBITDA | (4.51 M) | |||
| Net Income | (54.49 K) | |||
| Cash And Equivalents | 1.71 K | |||
| Total Debt | 407 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Health Pink Sheet
Health Sciences financial ratios help investors to determine whether Health Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Health with respect to the benefits of owning Health Sciences security.